- Case report
- Open Access
- Open Peer Review
Ectopic TSH-secreting pituitary tumor: a case report and review of prior cases
© Song et al.; licensee BioMed Central Ltd. 2014
- Received: 22 April 2014
- Accepted: 14 July 2014
- Published: 28 July 2014
Ectopic TSH-secreting pituitary adenoma (TSH-oma) is a very unusual disorder. To date, there are only four cases reported. It is difficult to distinguish ectopic cases from both regular TSH-omas and resistance to thyroid hormone (RTH).
A newly identified case of ectopic TSH-oma arising from the nasal pharynx was described, and reports of four prior cases were reviewed. The patient was a 41-year-old male who developed what appeared to be typical hyperthyroidism and atrial fibrillation in 2009. Thyroid function tests showed elevated basal levels of free T3 (FT3, 24.08 pmol/L), free T4 (FT4, 75.73 pmol/L), and serum TSH (7.26 μIU/ml). Both TSH-oma and resistance to thyroid hormone syndrome were considered. TRH stimulating test was negative, whereas octreotide inhibition test showed a reduction in TSH by 30.8%. Furthermore, a large space-occupying lesion located at the nasopharynx was found by computed tomography and magnetic resonance imaging (MRI). A normal pituitary was visualized. Ectopic TSH-oma was preliminarily established. Using an endoscopic endonasal approach, the tumor was resected. Histological features and immunophenotypes were consistent with those of TSH-secreting tumor. The levels of both free thyroxine and TSH returned to normal ranges the day after surgery and remained within normal range for 48 months.
Although exceedingly rare, ectopic TSH-oma should be considered for patients with inappropriate secretion of TSH with hyperthyroidism and pituitary tumor undetectable by computed tomography and MRI. To our knowledge, this is the first case followed up more than 4 years. The characteristics and successful interventions summarized in this report provide a guideline for clinicians.
- Ectopic TSH-secreting pituitary adenoma
- Resistance to thyroid hormone (RTH)
- TRH stimulating test
- Octreotide inhibition test
TSH-secreting pituitary adenomas (TSH-omas) are an unusual disorder, accounting for ~2% of all pituitary tumors . Ectopic TSH-oma is extremely rare. Since the first description of the disease by Cooper and colleagues in 1996, only four cases have been reported to date [2–5]. Here a newly identified case is reported, and the clinical and laboratory features of previous published cases are reviewed.
Plasma thyroid hormone and TSH levels
PTU 300 mg/d
PTU 300 mg/d
PTU 300 mg/d
24 h post surgery
48 m post surgery
Comparison of five ectopic TSH-omas
Age of onset (y)
Age of diagnosis
Location of tumor
no recurrence at 2 months
recurrence at 10 months
no recurrence at 4 months
no recurrence at 3 months
no recurrence at 48 months
consisted of monomorphous cells with secretory granules of small thyrotroph-like cells
consisted of polymorphous cells with secretory granules
Octreotide inhibition test
TRH stimulating test
This patient was diagnosed as ectopic TSH-oma in November 2009. Similar to the other cases, the patient went to see the doctor for hyperthyroidism with diffuse goiter and atrial fibrillation; ophthalmopathy, pretibial myxedema, and periodic paralysis were not presented. Additionally, the previous four cases had a common specific symptom of airway obstruction resulting from space occupying effects. Nevertheless, it was not evident in this patient, leading to overlook of existence of tumor by both the patient and physicians.
With regard to the phylogenetics of ectopic pituitary adenoma, it is broadly accepted that the tumor is derived from the embryonic residues of pituitary cells along the path of migration of Rathke's pouch. The anterior pituitary primordium appears at the fourth week of embryogenesis. The pituitary then divides into sellar and pharyngeal parts in the eighth week. The craniopharyngeal canal allows for migration of the pituitary tissue into the sphenoid sinus/bone or nasopharynx. Nasopharyngeal and sphenoid sinus or sphenoid bone ectopic pituitary tissue can be fully functional, since pharyngeal pituitary tissue begins to produce hormones around the 17-18th week of gestation (about 8 weeks later than sellar pituitary function begins) . Landolt and co-workers found that 90 - 100% of adults had ectopic pituitary tissue in the sphenoid sinus/bone . The pharyngeal hypophysis released all six normal pituitary hormones (ACTH, TSH, PRL, LH, FSH, and GH) . It is postulated that the embryonic residues of pituitary cells produce tumor lesion, and synthesize pituitary hormones.
Of note, the first case received radioactive iodine treatment without prior measurement of the TSH level. Although hyperthyroidism was abrogated, the consequence was hypothyroidism with an increased level of TSH. This obscured the nature of the disease and complicated the diagnostic process. This was the only case that received radiation therapy for the thyroid prior to final diagnosis. Therefore, it was difficult to determine whether the tumor was a primary ectopic TSH-secreting tumor or resulted from radioiodine thyroid ablation-induced hypothyroidism. Remission of the latter could be achieved by administration of thyroid hormones. Indeed, invasive transformation of the tumor and high occurrence of invasive macroadenomas were described in patients with previous thyroid ablation by surgery or radioiodine. It resembled the occurrence of Nelson’s syndrome after adrenalectomy for Cushing’s disease.
Ectopic TSH-oma and pituitary TSH-secreting tumor in the sellar area cannot be differentiated by their biological characteristics. Both present high levels of serum FT3 and FT4, in addition to either normal or high level of TSH. The difference between these two tumor types is that the ectopic TSH-oma has a normal pituitary gland and sellar turcica. Nowadays, with high-resolution CT and MRI, large pituitary adenomas are easy to find; moreover, it is not difficult to detect micro-adenomas either [9, 10].
TSH-omas are generally benign tumors. However, transformation of TSH-oma into carcinoma with multiple metastases and loss of pituitary α-GSU has been reported . TSH-secreting carcinoma could also develop from previously non-functioning pituitary adenoma . All five cases of ectopic TSH-omas had characteristics of benign tumors. Although tumors of some cases invaded into adjacent tissues, none showed distant metastasis .
Morphological characteristics of tumor cells were inconsistent including unitary shape, irregular morphology, and multiple types of cells. Cells contained abundant granular cytoplasm and round or oval nuclei. Relatively large amounts of blood sinuses existed in the tumor. The adenoma consisted of monomorphous cells as visualized by electron microscopy. Numerous secretory granules were scattered across the cytoplasm or along the cell membrane . They were similar in size and shape of electron dense with a diameter of 60-120 . In comparison, the tumor cells of this case were pleomorphic, and the size of their electron dense granules was larger with a diameter of 100-200 nm, and were scattered or clustered in the cytoplasm.
Immunohistochemical examination is essential for studying the nature of the tumor cells and hormone secretion. Almost all neuroendocrine tumors have enhanced expression of chromogranin A, synaptophysin, and neuron-specific enolase [6, 19]. Therefore, these proteins have been used as biomarkers of neuroendocrine tumor. Except for the case reported by Collie, strong expression of various neuroendocrine biomarkers, including chromogranin A, synaptophysin, and neuron-specific enolase was confirmed. As for cell proliferation, the amount of Ki-67-positive cells was less than 2%, suggesting that cell proliferation of the ectopic TSH-oma was low, in agreement with what was known of TSH-oma in situ. The types of hormones secreted by ectopic TSH-oma were not identical (Table 2). Except for the second case, GH expression in the tumor tissues was detected. In addition, augmentation of the expression of TSH and GH was also described in vitro . However, the serum level of GH in the fourth patient was normal, inconsistent with biochemical changes and clinical manifestation in vivo [20, 21]. The mechanism remains unclear. It may be due to lesser secretion of secondary hormone or limited release into blood.
The therapeutic approach in all five cases was adenomectomy. The primary objectives of the surgical treatment were to remove the ectopic TSH-oma, to eliminate the excessive secretion of TSH, and to restore euthyroidism. The prerequisite was to reduce the level of thyroid hormone to ease thyrotoxicosis prior to adenomectomy. The most common strategy is to take either anti-thyroid drugs (methimazole 20-30 mg/d or propylthiouracil 200-300 mg/d) or somatostatin analogs (octreotide, 100 μg, s.c., bid or tid. Sandostatin®, Novartis Pharma Schweiz AG, Switzerland) as well as propranolol (80-120 mg/d orally). Obviously, somatostatin analogs should be preferred theoretically, and this has been borne out in practice. For example, the TSH level of the fourth case returned to normal one day post octreotide treatment (100 μg, ih, q8h). Meanwhile, the levels of FT3 and FT4 declined to normal in 7 days. In contrast, it was difficult to control TSH and thyroid function with anti-thyroid drugs. In this case, PTU (300 mg/d) could not reduce free thyroxine to normal levels (Table 1). TSH and free thyroxine levels were normal within a few days , even within 24 hr after surgery in our case study. Apparently, it is feasible to treat TSH-omas by in situ radiotherapy. However, this intervention was not applied to all five cases of ectopic TSH-omas [2–5].
Given that somatostatin (somatotropin release-inhibiting hormone, SRIH) receptor was expressed in TSH-omas [23, 24], somatostatin analogues have been used to treat TSH-oma in situ. Somatostatin analogues are potent in reducing TSH secretion. Long-acting somatostatin analogues, including octreotide LAR, lanreotide SR, and lanreotide autogel were preferred [9, 10, 25, 26]. These medicines decreased TSH and α-GSU secretion, and restored euthyroidism. Circulating thyroid hormone levels were normalized in more than 95% of patients, and pituitary tumor mass shrinkage occurred in approximately 40% of patients . Furthermore, the efficiency of the somatostatin analogue was observed in an ectopic TSH-oma patient .
In toto, ectopic TSH-oma is extremely rare. To date, only four cases have been reported. The phylogenetic mechanism of ectopic TSH-oma should be similar to other ectopic pituitary tumors, which are probably derived from the embryonic residues of pituitary cells along the path of migration of Rathke's pouch. All five cases were found to have a mass in the nasopharyngeal region. Their clinical manifestations were almost the same as those of ordinary hyperthyroidism (high metabolic syndrome). Nevertheless, they all had high levels of TSH as well as increased serum free thyroxine. Alpha-GSU and α-GSU/TSH ratio are valuable for distinguishing TSH-oma from other diseases. Moreover, TRH stimulating and octreotide inhibition tests could differentiate ectopic TSH-oma from RTH. The primary therapy for ectopic TSH-oma is the resection of adenoma. Nonsurgical intervention through long-acting somatostatin analogues can suppress TSH secretion. Whether in situ radiation therapy could be an effective intervention remains unknown.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
This work was supported by NIH grant HL87017 and partially by AHA award 14GRNT20130034. The authors thank Ms. Yvette Chin (a freelance writer and science editor, Memorial Sloan-Kettering Cancer Center, New York) for her superb English edition.
- Scheithauer BW, Horvath E, Lloyd RV, Kovacs K: Diagnosis and Management of Pituitary Tumors. 2001, New Jersey: Humana PressGoogle Scholar
- Cooper DS, Wenig BM: Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid. 1996, 6 (4): 337-343. 10.1089/thy.1996.6.337.View ArticlePubMedGoogle Scholar
- Pasquini E, Faustini-Fustini M, Sciarretta V, Saggese D, Roncaroli F, Serra D, Frank G: Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur J Endocrinol. 2003, 148 (2): 253-257. 10.1530/eje.0.1480253.View ArticlePubMedGoogle Scholar
- Collie RB, Collie MJ: Extracranial thyroid-stimulating hormone-secreting ectopic pituitary adenoma of the nasopharynx. Otolaryngol Head Neck Surg. 2005, 133 (3): 453-454. 10.1016/j.otohns.2004.10.015.View ArticlePubMedGoogle Scholar
- Tong A, Xia W, Qi F, Jin Z, Yang D, Zhang Z, Li F, Xing X, Lian X: Hyperthyroidism caused by an ectopic thyrotropin-secreting tumor of the nasopharynx: a case report and review of the literature. Thyroid. 2013, 23 (9): 1172-1177. 10.1089/thy.2012.0574.View ArticlePubMedGoogle Scholar
- Thompson LD, Seethala RR, Muller S: Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature. Head Neck Pathol. 2012, 6 (1): 75-100. 10.1007/s12105-012-0336-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Landolt AM, Kleihues P, Heitz PU: Amyloid deposits in pituitary adenomas. Differentiation of two types. Arch Pathol Lab Med. 1987, 111 (5): 453-458.PubMedGoogle Scholar
- Ciocca DR, Puy LA, Stati AO: Identification of seven hormone-producing cell types in the human pharyngeal hypophysis. J Clin Endocrinol Metab. 1985, 60 (1): 212-216. 10.1210/jcem-60-1-212.View ArticlePubMedGoogle Scholar
- Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A: The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003, 148 (4): 433-442. 10.1530/eje.0.1480433.View ArticlePubMedGoogle Scholar
- Kienitz T, Quinkler M, Strasburger CJ, Ventz M: Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007, 157 (1): 39-46. 10.1530/EJE-07-0098.View ArticlePubMedGoogle Scholar
- Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD: Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999, 84 (2): 476-486. 10.1210/jcem.84.2.5505.View ArticlePubMedGoogle Scholar
- Beck-Peccoz P, Persani L, Mannavola D, Campi I: Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009, 23 (5): 597-606. 10.1016/j.beem.2009.05.006.View ArticlePubMedGoogle Scholar
- Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD: Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996, 17 (6): 610-638.PubMedGoogle Scholar
- Terzolo M, Orlandi F, Bassetti M, Medri G, Paccotti D, Cortelazzi D, Angeli A, Beck-Peccoz P: Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another cosecreting alpha-subunit and thyrotropin. J Clin Endocrinol Metab. 1991, 72 (2): 415-421. 10.1210/jcem-72-2-415.View ArticlePubMedGoogle Scholar
- Spada A, Bassetti M, Martino E, Giannattasio G, Beck-Peccoz P, Sartorio A, Vallar L, Baschieri L, Pinchera A, Faglia G: In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Invest. 1985, 8 (3): 193-198. 10.1007/BF03348476.View ArticlePubMedGoogle Scholar
- Beck-Peccoz P, Persani L: Medical management of thyrotropin-secreting pituitary adenomas. Pituitary. 2002, 5 (2): 83-88. 10.1023/A:1022360414062.View ArticlePubMedGoogle Scholar
- Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, Doppman JL, Oldfield EH, Weintraub BD: Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab. 1993, 76 (2): 529-533.PubMedGoogle Scholar
- Brown RL, Muzzafar T, Wollman R, Weiss RE: A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol. 2006, 154 (5): 639-643. 10.1530/eje.1.02141.View ArticlePubMedGoogle Scholar
- Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion. 2000, 62 (Suppl 1): 33-38.View ArticlePubMedGoogle Scholar
- Bertholon-Gregoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J: Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol. 1999, 140 (6): 519-527. 10.1530/eje.0.1400519.View ArticlePubMedGoogle Scholar
- Aylwin SJ, King A, Blenke A, Geddes JF, Wood DF, Monson JP, Burrin JM: Free α-subunit and intact TSH secretion in vitro are closely associated in human somatotroph adenomas. Eur J Endocrinol. 1998, 139 (4): 378-386. 10.1530/eje.0.1390378.View ArticlePubMedGoogle Scholar
- Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P: Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996, 81 (8): 3084-3090.PubMedGoogle Scholar
- Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M: Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment. Endocr J. 2007, 54 (3): 371-378. 10.1507/endocrj.K06-177.View ArticlePubMedGoogle Scholar
- Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J: Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab. 1992, 75 (2): 540-546.PubMedGoogle Scholar
- Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P: Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000, 85 (4): 1487-1491. 10.1210/jcem.85.4.6548.View ArticlePubMedGoogle Scholar
- Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P: Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf). 2005, 62 (2): 176-181. 10.1111/j.1365-2265.2004.02192.x.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/544/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.